The drug that we aim to develop for prevention of FNAIT is expected to work in exactly the same way as anti-D immunoglobulin which today is used to protect Rhesus-negative women from being immunized against RhD antigen on the surface of red blood cells from their foetuses.
The extensive use of anti-D immunoglobulin therapy has shown that immunoglobulins may effectively prevent a woman from being immunized by an antigen from her foetus. Fourty years experience with anti-D has also shown that this type of prophylaxis is very safe.
Development and prophylaxis of FNAIT:
(Click to enlarge image)